Tiziana Life Sciences Ltd (TLSA) is an innovative clinical-stage biotechnology company based in the UK, dedicated to the discovery and development of transformative therapeutic molecules and diagnostics aimed at addressing significant unmet medical needs within oncology and immunology. The company boasts a promising pipeline that includes advanced candidates targeting various cancers and autoimmune disorders, underpinned by its proprietary technologies designed to optimize patient outcomes. With a strong emphasis on scientific rigor and a strategic focus on efficient clinical trial management and regulatory navigation, Tiziana is poised to make a meaningful impact in the biopharmaceutical sector, positioning itself for sustainable growth and development. Show more

Location: 14/15 CONDUIT STREET, LONDON, UNITED KINGDOM, W1S 2XJ, London, W1S 2XJ, USA | Website: https://www.tizianalifesciences.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

192.1M

52 Wk Range

$0.63 - $2.60

Previous Close

$1.51

Open

$1.48

Volume

123,081

Day Range

$1.43 - $1.52

Enterprise Value

196.5M

Cash

7.251M

Avg Qtr Burn

-6.823M

Insider Ownership

43.95%

Institutional Own.

3.29%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Intranasal Foralumab Details Alzheimer's disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foralumab Details COVID-19	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milciclib (pan-CDK inhibitor) Details Hepatocellular carcinoma, Solid tumor/s	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Multiple System Atrophy	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS)	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foralumab (anti-CD3 mAb) Details Crohns disease	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Neurodegenerative disease, Amyotrophic lateral sclerosis	IND Acceptance decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.